KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBT (2020 - 2025)

Historic EBT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.2 million.

  • Recursion Pharmaceuticals' EBT fell 6958.45% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.7 million, marking a year-over-year decrease of 8688.99%. This contributed to the annual value of -$464.8 million for FY2024, which is 3994.24% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported EBT of -$162.2 million as of Q3 2025, which was down 6958.45% from -$171.9 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EBT ranged from a high of -$30.5 million in Q1 2021 and a low of -$202.6 million during Q1 2025
  • Over the past 5 years, Recursion Pharmaceuticals' median EBT value was -$76.7 million (recorded in 2023), while the average stood at -$92.7 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 15393.85% in 2021, then skyrocketed by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' EBT (Quarter) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then plummeted by 59.16% to -$97.1 million in 2023, then tumbled by 84.32% to -$178.9 million in 2024, then grew by 9.31% to -$162.2 million in 2025.
  • Its last three reported values are -$162.2 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.6 million during Q1 2025.